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The possible presence of Pneumocystis among
healthy adults was examined by detecting Pneumocystis
jirovecii–specific DNA in prospectively obtained oropharyn-
geal wash samples from 50 persons without underlying
lung disease or immunosuppression. Pneumocystis car-
riage, defined by detecting Pneumocystis DNA by nested
polymerase chain reaction in 2 independent analyses plus
successful mitochondrial large subunit ribosomal RNA typ-
ing by direct sequencing, was found in 20% of cases. All
carriers were asymptomatic, anti-HIV negative, and had
normal total lymphocyte and CD4+ cell counts. A second
sample obtained in the 6-month follow-up was positive in 2
of 9 available carriers. Genotype analysis showed different
polymorphisms; 85A/248C (40%) and 85C/248C (30%)
were most frequently observed. This study provides the
first evidence that P. jirovecii DNA can be frequently detect-
ed in the respiratory tract of immunocompetent adults,
which agrees with the hypothesis that the general popula-
tion could be a reservoir and source of this infection. 
P
neumocystis jirovecii (formerly known as
Pneumocystis carinii f. sp. hominis) (1) is the
causative agent of Pneumocystis pneumonia (PCP), one of
the most frequent and severe opportunistic infections in
immunocompromised patients (2). Pneumocystis organ-
isms represent a large group of species of atypical fungi
with universal distribution and pulmonary tropism, and
each species has a strong specificity for a given mam-
malian host species (3,4). 
Despite the advances made in understanding human
Pneumocystis infection, many aspects about its epidemiol-
ogy and natural history remain unclear. Serologic studies
have shown that specific antibodies to the pathogen can be
detected in most children early in life (5–7), which indi-
cates frequent exposure to this organism. Based on this
finding, disease in immunocompromised persons has long
been thought to result from reactivation of latent infection
acquired in childhood. However, animal and human stud-
ies have shown that elimination of Pneumocystis often
occurs after infection (8–9), which implies that the persist-
ence of latent organisms is limited.
Alternatively, the possibility that Pneumocystis can be
transmitted from person to person has been raised after the
reports of cluster outbreaks of PCP among solid-organ
transplant and oncology patients (10,11). Evidence sup-
porting the active or de novo airborne acquisition of the
organism from human sources has accumulated in the last
few years, including evidence for different Pneumocystis
genotypes in different episodes of PCP in the same patient
(12,13). Also, Pneumocystis DNA was detected in the
upper respiratory tract of healthy participants after close
contact with patients with PCP (14–16) and in air samples
from the rooms of PCP patients (17,18). Pneumocystis has
also been found in immunosuppressed patients without
PCP (19); these situations have been described as
Pneumocystis colonization or carriage. 
PCP patients, immunodeficient carriers, or transiently
parasitized immunocompetent persons have been hypothe-
sized to play a role as sources of Pneumocystis infection
(4). Although some earlier studies failed to detect the
organism in postmortem lung samples or bronchoalveolar
samples from immunocompetent adults (20,21), a recent
report indicates that Pneumocystis DNA can be frequently
detected in healthy infants (22). 
The ability to detect Pneumocystis in normal, healthy
persons is due to the development of more sensitive meth-
ods. Pneumocystis can now be detected in respiratory sam-
ples obtained by noninvasive methods using immuno-
fluorescence staining and polymerase chain reaction
(PCR) (23,24). By using these methods, Pneumocystis
carriage was found in 10% to 40% of immunocompetent
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an epidemiologic point of view, this high prevalence is dif-
ficult to determine if PCP or colonized immunosuppressed
patients and their close contacts are the only sources of
infection, since the persistence of latent organism in lung
appears to be time-limited (8,9). We tested the hypothesis
that in a normal community environment healthy adults
can be transiently colonized by Pneumocystis, and these
persons play a role in the persistence of the organism in the
human ecosystem. Identifying Pneumocystis sources is
essential to developing proper measures to prevent a dis-
ease that still causes substantial illness and death among
immunosuppressed patients. This study attempts to deter-




This prospective study included persons who 1) had not
been exposed to patients in a hospital environment within
the year before the study or 2) had not been diagnosed with
or were not suspected to have chronic lung disease, neo-
plasm, or immunosuppression of any cause. The first 50
persons evaluated in the Occupational Health Service of
the Virgen del Rocío University Hospital from February to
July 2003 who had not been excluded by the above crite-
ria were enrolled in this study.
The mean age of persons in this study group was 33.9
± 9.45 years. Nineteen (31.6%) were male. Distribution
according to professional standing was 28 (56%) newly
employed physician residents, 13 (26%) university or
common services staff members, and 9 (18%) administra-
tive staff. 
Each participant underwent a clinical-epidemiologic
examination, and oropharyngeal samples were collected
for analysis in the Occupational Health Service, a building
located outside the hospital environment. Demographic
variables, underlying medical conditions, habits, and
antimicrobial therapy were recorded by using a standard-
ized form. Informed consent was obtained from partici-
pants. The study protocol was designed and performed
according to the Helsinki Declaration and was approved by
the ethics committee, Virgen del Rocío University
Hospital, Seville, Spain. 
For all Pneumocystis carriers, a complete clinical and
biologic evaluation was performed, including physical
examination, chest x-ray, conventional blood work, anti-
HIV serologic examination, and peripheral blood lympho-
cyte subsets analyses. Volunteers who were designated P.
jirovecii carriers were reexamined after 6 months, when
oropharyngeal samples were again obtained. 
Case Definition
A Pneumocystis carrier was defined as a person who
met all of the following conditions: 1) no clinical history
of PCP, 2) respiratory specimen with detectable P. jirovecii
DNA by nested PCR in 2 independent analyses, and 3)
successful mitochondrial large subunit ribosomal RNA
(mtLSU-rRNA) typing of the respiratory specimen by
direct sequencing at least once. Persons who did not meet
these criteria were considered Pneumocystis-negative.
Sampling and Detecting P. jirovecii
Oropharyngeal wash samples were obtained by gar-
gling with 10 mLof sterile physiologic serum (0.9% NaCl)
for a period of 1 min. Samples were centrifuged at 2,900 x
g for 5 min and kept frozen at –20°C until DNA was
extracted. 
After digestion with proteinase K at 56ºC for 2 h, DNA
from 2 aliquots of each oropharyngeal wash sample was
extracted on 2 days by using a commercial kit from Qiagen
(Hilden, Germany). Sham extractions, carried out in paral-
lel with the processing of samples, were also included to
control for contamination in the DNA extraction step. The
purified DNAwas used as a template to amplify the region
containing mtLSU-rRNA by nested PCR, as described
elsewhere (27,28). The sensitivity of this nested PCR assay
is 1 organism/µL. Briefly, in the first amplification round,
the external primers pAZ102-E (5′-GAT GGC TGT TTC
CAA GCC CA-3′) and pAZ102-H (5′-GTG TAC GTT
GCA AAG TAC TC-3′) were used. This amplification
yields a 346–base pair (bp) fragment. The second round of
amplification used the primers pAZ102-X (5′-GTG AAA
TAC AAATCG GAC TAG G-3′) and pAZ102-Y (5′-TCA
CTTAATATTAAT TGG GGAGC-3′) and yielded a 260-
bp product. Forty cycles of amplification were carried out
for both rounds. 
The amplification products were analyzed by elec-
trophoresis on a 1.5% agarose gel containing ethidium bro-
mide, and the bands were visualized by UV light. To
prevent false-positives from contamination, pipettes with
filters were used in all manipulations. DNA extraction,
preparation of the reaction mixture, PCR amplification,
and detection were performed in different areas under a
laminar flow hood. To detect any cross-contamination, all
PCRs were performed with negative controls and sterile
water.
The products from nested PCR amplification were puri-
fied by using Sephacryl S-400 columns (Amersham
Pharmacia Biotech AB, Uppsala, Sweden) and reamplified
by using ABI Prism dRhodamine Terminator Cycle
Sequencing Ready Reaction Kit (PE Applied Biosystems,
Foster City, CA, USA). Then, for each reaction, 5 µLo f
PCR product, 4 µL terminator-ready reaction mix, and 3
pmol of primer were added. The extension products were
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minators. Each sample pellet was resuspended in 12.5 µL
of template suppression reagent and heated at 95ºC for 3
min for denaturation. Electrophoresis was carried out on
the ABI prism 310 sequencer (PE Applied Biosystems)
according to manufacturer’s recommendations. The
sequenced DNA fragments were analyzed by using
Sequence Navigator v.1.0.1 (PE Applied Biosystems). 
In the specimens of carriers, the P. jirovecii dihy-
dropteroate synthase (DHPS) locus was analyzed by PCR
restriction fragment length polymorphism (RFLP), as pre-
viously described (28). In brief, the single-copy gene of
DHPS was amplified by the primers DHPS-3 (5′-GCG
CCT ACA CAT ATT ATG GCC ATT TTAAAT C-3′) and
DHPS-4 (5′-GGAACT TTC AAC TTG GCAACC AC-3′)
by using a touchdown-PCR protocol, yielding a 370-bp
fragment. The PCR product was divided into 3 aliquots.
One was used to confirm the presence of a 370-bp frag-
ment from the DHPS gene. The second and third aliquots
were used to identify wild-type sequences versus muta-
tions in codons 55 and 57 by RFLP with AccI and HaeIII
(Roche Diagnostics, Mannheim, Germany), respectively.
When the mutation is present, a 370-bp band appears.
After RFLP in wild-type samples, bands appear at 229 bp
and 141 bp with AccI and at 221 bp and 149 bp with
HaeIII.
Laboratory Studies
Peripheral blood lymphocyte subsets were determined
by using a flow cytometer (Cytoron Absolute, Ortho,
Raritan, NJ, USA) after incubation with monoclonal anti-
bodies OKT3, OKT4, and OKT8 (Ortho). Serum anti-HIV
antibodies were determined by a commercial enzyme-
linked immunosorbent assay (ELISA) (Multispot HIV-
1/HIV-2 rapid test, BioRad, Hercules, CA, USA). The
results were interpreted according to the manufacturer’s
recommendations. 
Statistical Analysis
The chi-square test was used for assessing differences
between proportions. Results were considered significant
at p < 0.05. Statistical analyses were performed by using
the Statistical Package for Serial Studies for personal com-
puters (SPSS version 12, SPSS Inc., Chicago, IL, USA).
Results 
P. jirovecii DNA in 12 of 50 samples was successfully
amplified twice by nested PCR. The mtLSU-rRNA frag-
ment locus was successfully typed in 10 of the 12 samples
in which mtLSU-rRNA had been amplified. Thus, P.
jirovecii carriage was detected in 20% of the participants.
To assess the reproducibility and consistency of results,
serial samples were obtained with a 2-day interval in 5 par-
ticipants (1 carrier and 4 noncarriers). In all of them, con-
sistent positive and negative patterns of results were
obtained (positive PCR test after a positive result and neg-
ative PCR test after a negative result).
The DHPS primer sets amplified a 370-bp band in 7
(70%) of 10 carriers. In all positive specimens with the
DHPS-based PCR assay, the RFLP technique identified a
wild DHPS genotype (Table). 
Results of physical examination were normal for
Pneumocystis carriers. All were anti-HIV negative and had
normal total lymphocyte and CD4+ cell counts. Chest radi-
ographs were normal in 8 participants, and 1 participant
had an apical cystic bullae (Table). Only 1 person had
taken steroids for a brief period in the 6 months before the
study. No differences were detected due to age, sex, pro-
fession, alcohol intake, and smoking habit between P.
jirovecii carriers and noncarriers.
Five known mtLSU-rRNA types are described for this
Pneumocystis gene locus (15); 4 genotypes were isolated
in the current study. Genotypes at this locus were identi-
fied on the basis of polymorphisms at nucleotide positions
85 and 248. Genotype 2 (85:A/248:C) was observed in 4
cases, genotype 1 (85:C/248:C) in 3 cases, genotype 3
(85:T/248:C) in 2 cases, and genotype 4 (85:C/248:T) in
the remaining case (Table). 
During the follow-up, all carriers were asymptomatic
for pulmonary disease. Pneumocystis DNA was detected
by PCR in a second oropharyngeal wash obtained 6
months after the first in 2 (22.2%) of the 9 available carri-
ers. Neither sample was typed because of insufficient
quantity of PCR product. 
Discussion 
This study on immunocompetent healthy adults docu-
ments that P. jirovecii DNA can be detected by sensitive
DNA amplification techniques by using noninvasive sam-
pling of the respiratory tract. DNA detection does not
establish the existence of infectious intact organisms.
However, in animal models, detecting Pneumocystis DNA
in nasal and oral samples is a good indicator that the organ-
ism is in the lung (29). Also, experiments show that
Pneumocystis organisms can replicate in the lung alveolus
of immunocompetent hosts and remain infectious (30).
Thus, our results agree with the hypothesis that the gener-
al human population could play an important role as a
reservoir and source of P. jirovecii infection and support
the saprophytic nature of this pathogen in humans. 
An important finding of this study is that Pneumocystis
DNA was not detected in >75% of the immunocompetent
colonized adults within 6 months, which suggests the pos-
sible transience of the carrier state in healthy persons.
This observation agrees with previous reports that show
that most immunocompetent healthcare workers who
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(15,16). 
The number of persons examined in this study suffi-
ciently demonstrated that P. jirovecii is an organism fre-
quently found in healthy adults in the normal community.
Since participants were all affiliated in some way with the
Virgen del Rocío University Hospital in Seville, Spain, a
broader group of healthy adults would need to be exam-
ined to estimate the prevalence of the carriers in the gener-
al population. Carrying out the study in a hospital could
have somewhat biased the results, although we excluded
persons with prior exposure to patients within the hospital
and collected samples in a building outside the hospital.
The accepted current diagnostic standard for
Pneumocystis infection is the direct demonstration of the
stained microorganism in respiratory samples. Techniques
based on PCR amplification of specific genome regions
that provide high sensitivity are now widely used to diag-
nose several infectious diseases. These technical advances
have allowed us to detect infections with samples obtained
by noninvasive methods and in samples with low pathogen
load. Different studies involving both sputum and bron-
choalveolar lavage specimens have demonstrated the high-
er sensitivity of these techniques compared to
conventional staining and monoclonal antibody immuno-
histochemical techniques (31,32). The main drawback to
PCR is the possibility of false-positives (usually because
of contamination) and the absence of rapid culture meth-
ods to confirm the PCR amplification results obtained. We
avoided potential false-positives by adopting stringent pre-
cautionary measures and by examining the PCR signal
from 2 different genes of P. jirovecii.
The mtLSU-rRNA gene was selected for genotyping
because it has a high degree of genetic conservation and is
useful for detecting intraspecific differences between pop-
ulations (33). The allelic frequency distribution patterns at
this gene seen in the present study are similar to those
reported in AIDS-associated PCP cases in a large study
conducted in 5 cities in the United States (33). In that
study, P. jirovecii genotypes were correlated with the place
of diagnosis, rather than the person’s place of birth. Our
results support the concept of a community source of the
infectious agents. Furthermore, an epidemiologic study
was recently performed in patients in Spain with various
pulmonary diseases. By also analyzing mtLSU-rRNA
types, we found a high prevalence of genotype 1 (45%)
and genotype 3 (40%) and lower of genotype 2 (10%) (28).
In contrast, in the present study, genotype 2 was the most
prevalent, whereas it was low in the pulmonary patient
study, and genotype 3 was more frequently found in pul-
monary patients than in normal healthy adults. Patients
with pulmonary disorders may have a greater susceptibili-
ty to genotype 3. 
In our study, the rate of carriers identified as having the
DHPS gene is 70%. The low amplification rate obtained is
perhaps related to a low pathogen load in the samples.
However, this rate is similar to that reported for AIDS
patients with PCP in previously published studies (33).
In the last decade, PCR technologies have shown that
immunocompromised patients without PCP can be sub-
clinically infected with Pneumocystis (19). In addition, a
high prevalence of Pneumocystis is seen among immuno-
competent patients with chronic pulmonary disorders
(25,26,34), patients with small-cell lung carcinoma (35),
or pregnant women (36). The pathogen has been detected
in immunocompetent contacts of patients with PCP and in
immunocompetent healthcare workers, whether or not they
had contact with immunocompromised patients (15,16).
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ly transiently colonized; Pneumocystis can replicate
actively in their lungs and can be transmitted to another
host (30,37). Moreover, postmortem lung screening using
conventional staining for Pneumocystis showed small
numbers of the organism in the lungs of immunocompetent
individuals (38). 
Thus, substantial evidence exists of Pneumocystis colo-
nization of healthy persons, and our findings are consistent
with these observations. Most previous studies that failed
to find the organism on autopsy (21) or in respiratory sam-
ples (14,29,31,36,39) from immunocompetent persons
were performed on only a few persons. In some cases, fail-
ure was probably related to the use of either single PCR
(31) or a less sensitive PCR (39). In others, failure could
be related to the use of sputum or nasal secretions
(14,29,36) that may have had lower numbers of organisms
than in the oropharyngeal wash we analyzed or because of
different procedures used for analyses (29). Protocols for
acquiring and processing respiratory samples and analyti-
cal probes and methods should be standardized to enable
better comparisons between studies performed in different
laboratories.
In summary, immunocompetent healthy adults might
harbor short-lived infections that could be transmitted to
other immunocompetent host in whom a transient infec-
tion can develop. Similarly, infants can become infected
and a primary infection can develop, and immunosup-
pressed, susceptible people can become infected and clini-
cal PCP can develop. Today, we know that human
pneumocystosis is anthroponotic. Our findings may sug-
gest that healthy adults represent a new dynamic reservoir
and source of infection for human Pneumocystis species.
Immunocompetent carriers in community ecosystems
might present a public health issue that merits further
research.
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